Switch to:
Also traded in: Brazil, Chile, Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.66
CVS's Cash-to-Debt is ranked lower than
93% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.15 vs. CVS: 0.66 )
Ranked among companies with meaningful Cash-to-Debt only.
CVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.14 Max: 5.05
Current: 0.66
0.04
5.05
Equity-to-Asset 0.28
CVS's Equity-to-Asset is ranked higher than
56% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.38 vs. CVS: 0.28 )
Ranked among companies with meaningful Equity-to-Asset only.
CVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.51 Max: 0.67
Current: 0.28
0.27
0.67
Debt-to-Equity 1.72
CVS's Debt-to-Equity is ranked lower than
68% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.59 vs. CVS: 1.72 )
Ranked among companies with meaningful Debt-to-Equity only.
CVS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04  Med: 0.34 Max: 1.83
Current: 1.72
0.04
1.83
Debt-to-EBITDA 7.12
CVS's Debt-to-EBITDA is ranked lower than
67% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.82 vs. CVS: 7.12 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CVS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.14  Med: 1.39 Max: 7.12
Current: 7.12
1.14
7.12
Interest Coverage 4.45
CVS's Interest Coverage is ranked lower than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.81 vs. CVS: 4.45 )
Ranked among companies with meaningful Interest Coverage only.
CVS' s Interest Coverage Range Over the Past 10 Years
Min: 4.45  Med: 11.43 Max: 15.55
Current: 4.45
4.45
15.55
Piotroski F-Score: 6
Altman Z-Score: 2.99
WACC vs ROIC
8.49%
12.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 5.18
CVS's Operating Margin % is ranked lower than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.49 vs. CVS: 5.18 )
Ranked among companies with meaningful Operating Margin % only.
CVS' s Operating Margin % Range Over the Past 10 Years
Min: 5.15  Med: 6.24 Max: 6.91
Current: 5.18
5.15
6.91
Net Margin % 1.65
CVS's Net Margin % is ranked lower than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.87 vs. CVS: 1.65 )
Ranked among companies with meaningful Net Margin % only.
CVS' s Net Margin % Range Over the Past 10 Years
Min: 1.65  Med: 3.49 Max: 3.74
Current: 1.65
1.65
3.74
ROE % 8.48
CVS's ROE % is ranked higher than
65% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.89 vs. CVS: 8.48 )
Ranked among companies with meaningful ROE % only.
CVS' s ROE % Range Over the Past 10 Years
Min: 8.48  Med: 11.33 Max: 17.77
Current: 8.48
8.48
17.77
ROA % 2.65
CVS's ROA % is ranked higher than
61% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.25 vs. CVS: 2.65 )
Ranked among companies with meaningful ROA % only.
CVS' s ROA % Range Over the Past 10 Years
Min: 2.65  Med: 5.99 Max: 6.99
Current: 2.65
2.65
6.99
ROC (Joel Greenblatt) % 53.57
CVS's ROC (Joel Greenblatt) % is ranked higher than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 65.45 vs. CVS: 53.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 41.93  Med: 53.25 Max: 68.32
Current: 53.57
41.93
68.32
3-Year Revenue Growth Rate 14.80
CVS's 3-Year Revenue Growth Rate is ranked higher than
74% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.60 vs. CVS: 14.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.3  Med: 12.2 Max: 19.5
Current: 14.8
-13.3
19.5
3-Year EBITDA Growth Rate 9.70
CVS's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.70 vs. CVS: 9.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -25.3  Med: 9.4 Max: 63.9
Current: 9.7
-25.3
63.9
3-Year EPS without NRI Growth Rate 17.70
CVS's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 17.70 vs. CVS: 17.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.3  Med: 15.2 Max: 112.8
Current: 17.7
-48.3
112.8
» CVS's 30-Y Financials

Financials (Next Earnings Date: 2019-02-20)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

CVS Guru Trades in Q1 2018

Andreas Halvorsen 950,311 sh (New)
Jerome Dodson 346,000 sh (New)
Philippe Laffont 5,539 sh (New)
Vanguard Health Care Fund 4,518,118 sh (+36.57%)
Bill Nygren 6,300,000 sh (+133.33%)
Ken Fisher 300,425 sh (+28.75%)
Robert Olstein 185,000 sh (+35.53%)
T Rowe Price Equity Income Fund 2,390,000 sh (+148.96%)
Richard Pzena 703,641 sh (+0.37%)
Tom Gayner 275,000 sh (+3.00%)
Jeff Auxier 69,614 sh (+0.37%)
Paul Tudor Jones 36,809 sh (+30.44%)
Jim Simons 1,919,505 sh (+1.63%)
Caxton Associates 17,245 sh (+16.97%)
Barrow, Hanley, Mewhinney & Strauss 18,102,755 sh (+16.68%)
Pioneer Investments 1,477,571 sh (+8.66%)
Larry Robbins 7,794,388 sh (+14.26%)
Ray Dalio 670,184 sh (+59.30%)
Jeremy Grantham 220,000 sh (unchged)
NWQ Managers Sold Out
Jeremy Grantham Sold Out
David Dreman 9,331 sh (-10.57%)
Joel Greenblatt 512,294 sh (-46.18%)
Charles Brandes 60,137 sh (-0.41%)
John Buckingham 43,252 sh (-4.59%)
PRIMECAP Management 3,377,691 sh (-0.47%)
Steven Cohen 814,500 sh (-41.44%)
First Pacific Advisors 52,660 sh (-14.46%)
Mario Gabelli 657,470 sh (-14.08%)
Charles de Vaulx 480,122 sh (-31.41%)
» More
Q2 2018

CVS Guru Trades in Q2 2018

Leon Cooperman 406,600 sh (New)
Ken Fisher 317,675 sh (+5.74%)
T Rowe Price Equity Income Fund 2,700,000 sh (+12.97%)
Charles Brandes 62,516 sh (+3.96%)
Richard Pzena 722,786 sh (+2.72%)
John Buckingham 44,341 sh (+2.52%)
PRIMECAP Management 3,491,231 sh (+3.36%)
Steven Cohen 822,000 sh (+0.92%)
Barrow, Hanley, Mewhinney & Strauss 18,322,542 sh (+1.21%)
Ray Dalio 698,767 sh (+4.26%)
Jerome Dodson 680,000 sh (+96.53%)
Bill Nygren 7,865,000 sh (+24.84%)
Vanguard Health Care Fund 4,518,118 sh (unchged)
Tom Gayner 275,000 sh (unchged)
First Pacific Advisors 52,660 sh (unchged)
Charles de Vaulx 480,122 sh (unchged)
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Philippe Laffont Sold Out
Jim Simons Sold Out
Robert Olstein 164,000 sh (-11.35%)
Joel Greenblatt 251,945 sh (-50.82%)
Caxton Associates 6,542 sh (-62.06%)
Pioneer Investments 1,204,837 sh (-18.46%)
Larry Robbins 5,422,240 sh (-30.43%)
Mario Gabelli 610,040 sh (-7.21%)
Jeff Auxier 69,499 sh (-0.17%)
» More
Q3 2018

CVS Guru Trades in Q3 2018

Diamond Hill Capital 2,598,273 sh (New)
Philippe Laffont 2,587 sh (New)
Murray Stahl 3,114 sh (New)
Dodge & Cox 15,125,686 sh (New)
T Rowe Price Equity Income Fund 2,780,000 sh (+2.96%)
Barrow, Hanley, Mewhinney & Strauss 19,815,800 sh (+8.15%)
PRIMECAP Management 3,659,811 sh (+4.83%)
Pioneer Investments 2,709,469 sh (+124.88%)
Larry Robbins 6,614,954 sh (+22.00%)
Joel Greenblatt 532,925 sh (+111.52%)
Steven Cohen 1,953,957 sh (+137.71%)
John Buckingham 44,964 sh (+1.41%)
Jerome Dodson 680,000 sh (unchged)
Vanguard Health Care Fund 4,518,118 sh (unchged)
Tom Gayner 275,000 sh (unchged)
First Pacific Advisors Sold Out
Caxton Associates Sold Out
Ken Fisher 17,049 sh (-94.63%)
Mario Gabelli 550,317 sh (-9.79%)
Robert Olstein 128,000 sh (-21.95%)
Charles Brandes 60,282 sh (-3.57%)
Richard Pzena 719,080 sh (-0.51%)
Ray Dalio 92,216 sh (-86.80%)
Leon Cooperman 394,600 sh (-2.95%)
Jeff Auxier 69,324 sh (-0.25%)
Charles de Vaulx 472,976 sh (-1.49%)
Bill Nygren 7,300,000 sh (-7.18%)
» More
Q4 2018

CVS Guru Trades in Q4 2018

John Hussman 35,800 sh (New)
Chris Davis 1,130,059 sh (New)
Jim Simons 1,323,374 sh (New)
Ken Fisher 17,111 sh (+0.36%)
Vanguard Health Care Fund 11,783,465 sh (+160.80%)
Charles Brandes 62,197 sh (+3.18%)
Diamond Hill Capital 5,208,653 sh (+100.47%)
PRIMECAP Management 4,499,213 sh (+22.94%)
Ray Dalio 597,410 sh (+547.84%)
Jeff Auxier 83,495 sh (+20.44%)
Murray Stahl 3,690 sh (+18.50%)
Philippe Laffont 6,967 sh (+169.31%)
Dodge & Cox 16,048,889 sh (+6.10%)
Leon Cooperman 795,900 sh (+101.70%)
Pioneer Investments 3,108,956 sh (+14.74%)
Larry Robbins 8,489,991 sh (+28.35%)
Tom Gayner 275,000 sh (unchged)
Jerome Dodson 497,728 sh (-26.80%)
T Rowe Price Equity Income Fund 2,750,000 sh (-1.08%)
Mario Gabelli 533,013 sh (-3.14%)
Richard Pzena 718,382 sh (-0.10%)
Robert Olstein 127,000 sh (-0.78%)
Steven Cohen 1,103,442 sh (-43.53%)
Joel Greenblatt 287,672 sh (-46.02%)
Barrow, Hanley, Mewhinney & Strauss 19,170,872 sh (-3.25%)
» More
» Details

Insider Trades

Latest Guru Trades with CVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Plans » Health Care Plans    NAICS: 621399    SIC: 8099
Compare:NYSE:ANTM, NYSE:AET, NAS:ESRX, NYSE:CI, NYSE:HUM, NYSE:CNC, NYSE:WCG, NYSE:MOH, BSP:ODPV3, BSP:QUAL3, NAS:MGLN, XPAR:GDS, NAS:HIIQ, OSTO:MCOV B, ROCO:6665, ATH:IATR, ASX:ONT, TSXV:NAC, MIL:HI, OTCPK:HFRN » details
Traded in other countries:CVSH34.Brazil, CVS.Chile, CVS.Germany, CVS.Mexico,
Headquarter Location:USA
CVS Health Corp operates in the healthcare sector. Its primary business is that of operating retail pharmacies. The company has three reportable segments namely Pharmacy Services, Retail/LTC, and Corporate.

CVS Health has vertically integrated one of the largest retail pharmacy chains in the United States with one of the largest pharmacy benefit managers. This combination makes it one of the premier healthcare firms in the U.S. The company processes approximately 1.3 billion prescriptions per year and operates more than 10,000 retail pharmacies across the U.S. The firm is now seeking to acquire Aetna, which will further extend its vertical reach and create the most integrated healthcare player in the U.S.

Guru Investment Theses on CVS Health Corp

Bill Nygren Comments on CVS Health - Jan 09, 2019

Unlike many of the high P/E stocks in this sector, our largest holding—CVS Health—sells at only 10 times expected earnings. In November, CVS (NYSE:CVS) merged its drugstore business with the health insurer Aetna, based on the belief that sharing facilities and information across the two businesses would lower health care costs and increase profitability. The stock market doesn’t appear to give it any credit for that possibility.



From Bill Nygren (TradesPortfolio)'s Oakmark Fund fourth-quarter 2018 market commentary.



Check out Bill Nygren latest stock trades

Jerome Dodson Comments on CVS Health - Oct 31, 2018

Drugstore chain CVS Health (NYSE:CVS) increased the Fund’s return by 111 bps, as the stock went from $64.35 to $78.72 for a total return of 23.3%. Shares moved higher, after the company announced better-than-expected profits and raised earnings guidance for the year.

Investors had been concerned about the company’s policy of retaining rebates from drug companies, but management disclosed that this accounted for only 3% of its earnings, much lower than investors feared. The stock kept moving higher toward the end of the quarter, when the Department of Justice approved Cigna’s acquisition of Express Scripts, indicating that CVS’s acquisition of Aetna would probably be approved in the near future.

From Jerome Dodson (Trades, Portfolio)'s third-quarter 2018 Endeavor Fund shareholder letter.

Check out Jerome Dodson latest stock trades

Dodge & Cox Comments on CVS Health - Oct 16, 2018

During the third quarter, we initiated five new holdings in the Fund, with the largest new purchase being CVS Health. CVS Health (NYSE:CVS) operates the largest pharmacy benefit manager (PBM) and retail pharmacy chain in the United States. Concerns about pricing pressures and potential competitive threats from Amazon have lowered CVS Health’s valuation to a 20-year low. However, we believe that CVS Health’s valuation—approximately 11 times forward earnings—does not reflect the strength of its franchise. The company holds the number one position in each of its five primary business lines: PBM; specialty pharmacy; retail/mail pharmacy; Medicare prescription drug plan; and, long-term care. In addition, over the past five years, CVS Health’s shareholder-friendly management team has improved return on invested capital, generated robust free cash flow, and gained significant market share. The company acquired Caremark (a PBM) in 2006 and successfully transitioned Caremark’s prescription script volume into CVS stores. CVS Health now plans to move into managed care with its pending acquisition of Aetna (the third-largest managed care company in the United States), which is expected to close by the end of 2018. On September 30, CVS Health shares constituted 1.0% of the Fund’s portfolio.



From Dodge & Cox's third quarter 2018 shareholder commentary.



Check out Dodge & Cox latest stock trades

Bill Nygren Comments on CVS Health Corp - Jan 11, 2018

CVS Health Corporation (CVS - $73)(NYSE:CVS)
CVS is well positioned in a U.S. health care system that rewards scale, as the company owns the nation’s largest pharmacy benefit manager (PBM), the largest retail pharmacy and the largest retail clinic. Both the PBM and retail pharmacy segments are as concentrated as they have ever been, and we believe these lines of business protect existing players and pose serious challenges for new entrants. After underperforming the S&P 500 by nearly 60% over the past two years, CVS is now valued at less than 12x next year’s consensus earnings after adding back amortization of intangible assets. In our view, the market is underestimating the durability of the company’s competitive advantages across multiple end markets. Additionally, the pending acquisition of Aetna, Inc. would bring together two forward-thinking management teams and give them a broad suite of assets through which to address sector-wide trends, like the shift toward value-based care models and the increasing “consumerization” of health care.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund fourth quarter 2017 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about CVS Health Corp

CVS Health Corp Falls on 4th-Quarter Results The US retail pharmacy beats consensus on adjusted earnings but misses expectations on revenues
CVS Health Corp. (NYSE:CVS), the large U.S. retail pharmacy and health care company, posted results for the final trimester of 2018 on Wednesday before market open. Read more...
CVS Health to Present at the SVB Leerink Global Healthcare Conference
Factors of Influence in 2019, Key Indicators and Opportunity within CVS Health, Solaris Oilfield Infrastructure, SK Telecom Co., Energizer, Emergent Biosolutions, and Quad Graphics — New Research Emphasizes Economic Growth
CVS Health Corporation To Hold Fourth Quarter 2018 Conference Call
Vanguard Health Care Fund Boosts CVS Health, Allergan Fund's largest buys of the 4th quarter
The Vanguard Health Care Fund (Trades, Portfolio), which offers investors low-cost exposure to domestic and foreign companies involved in various aspects of the health care industry, bought shares of the following stocks in the fourth quarter. Read more...
CVS Health Offering No Cost Heart Health Screenings This Valentine's Day In Support of Women's Heart Health
CVS Health Expanding Free Wellness Screenings Statewide in California
Aetna Announces Attain, a Personalized Well-being Experience that Combines Health History with Apple Watch Information to Empower Better Health
CVS Health Announces Transaction With Vitality Re X
CVS Pharmacy Unveils New Beauty Aisles Reflecting Significant Progress in Commitment to Transparency and New Standards for Beauty Imagery

Ratios

vs
industry
vs
history
PE Ratio 21.54
CVS's PE Ratio is ranked higher than
90% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. CVS: 21.54 )
Ranked among companies with meaningful PE Ratio only.
CVS' s PE Ratio Range Over the Past 10 Years
Min: 9.35  Med: 16.74 Max: 27.17
Current: 21.54
9.35
27.17
Forward PE Ratio 9.45
CVS's Forward PE Ratio is ranked higher than
85% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.27 vs. CVS: 9.45 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.54
CVS's PE Ratio without NRI is ranked higher than
90% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. CVS: 21.54 )
Ranked among companies with meaningful PE Ratio without NRI only.
CVS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.35  Med: 16.61 Max: 27.17
Current: 21.54
9.35
27.17
Price-to-Owner-Earnings 706.97
CVS's Price-to-Owner-Earnings is ranked higher than
62% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.47 vs. CVS: 706.97 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CVS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.4  Med: 17.49 Max: 871.74
Current: 706.97
8.4
871.74
PB Ratio 1.81
CVS's PB Ratio is ranked higher than
88% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.42 vs. CVS: 1.81 )
Ranked among companies with meaningful PB Ratio only.
CVS' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 1.85 Max: 3.37
Current: 1.81
1.01
3.37
PS Ratio 0.35
CVS's PS Ratio is ranked higher than
80% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.73 vs. CVS: 0.35 )
Ranked among companies with meaningful PS Ratio only.
CVS' s PS Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.52 Max: 0.88
Current: 0.35
0.33
0.88
Price-to-Free-Cash-Flow 15.43
CVS's Price-to-Free-Cash-Flow is ranked higher than
72% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.78 vs. CVS: 15.43 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CVS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.28  Med: 17.93 Max: 51.94
Current: 15.43
8.28
51.94
Price-to-Operating-Cash-Flow 10.62
CVS's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.15 vs. CVS: 10.62 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.72  Med: 11.12 Max: 19.92
Current: 10.62
6.72
19.92
EV-to-EBIT 16.71
CVS's EV-to-EBIT is ranked higher than
86% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.89 vs. CVS: 16.71 )
Ranked among companies with meaningful EV-to-EBIT only.
CVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 10.8 Max: 17.7
Current: 16.71
6.2
17.7
EV-to-EBITDA 11.92
CVS's EV-to-EBITDA is ranked higher than
76% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.81 vs. CVS: 11.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
CVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1  Med: 8.7 Max: 13.4
Current: 11.92
5.1
13.4
EV-to-Revenue 0.55
CVS's EV-to-Revenue is ranked higher than
74% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.01 vs. CVS: 0.55 )
Ranked among companies with meaningful EV-to-Revenue only.
CVS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 0.6 Max: 1
Current: 0.55
0.4
1
PEG Ratio 1.99
CVS's PEG Ratio is ranked higher than
69% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. CVS: 1.99 )
Ranked among companies with meaningful PEG Ratio only.
CVS' s PEG Ratio Range Over the Past 10 Years
Min: 0.28  Med: 1.48 Max: 4.6
Current: 1.99
0.28
4.6
Shiller PE Ratio 17.23
CVS's Shiller PE Ratio is ranked higher than
92% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 27.53 vs. CVS: 17.23 )
Ranked among companies with meaningful Shiller PE Ratio only.
CVS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.33  Med: 22.82 Max: 38.92
Current: 17.23
15.33
38.92
Current Ratio 2.44
CVS's Current Ratio is ranked lower than
64% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. CVS: 2.44 )
Ranked among companies with meaningful Current Ratio only.
CVS' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.53 Max: 2.64
Current: 2.44
1.02
2.64
Quick Ratio 1.94
CVS's Quick Ratio is ranked lower than
84% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. CVS: 1.94 )
Ranked among companies with meaningful Quick Ratio only.
CVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.52 Max: 1.94
Current: 1.94
0.2
1.94
Days Inventory 34.03
CVS's Days Inventory is ranked lower than
82% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.84 vs. CVS: 34.03 )
Ranked among companies with meaningful Days Inventory only.
CVS' s Days Inventory Range Over the Past 10 Years
Min: 34.03  Med: 38.19 Max: 50.42
Current: 34.03
34.03
50.42
Days Sales Outstanding 14.09
CVS's Days Sales Outstanding is ranked higher than
55% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 30.58 vs. CVS: 14.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.09  Med: 23.74 Max: 28.31
Current: 14.09
14.09
28.31
Days Payable 20.26
CVS's Days Payable is ranked lower than
80% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 42.32 vs. CVS: 20.26 )
Ranked among companies with meaningful Days Payable only.
CVS' s Days Payable Range Over the Past 10 Years
Min: 16.58  Med: 19.59 Max: 21.57
Current: 20.26
16.58
21.57

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.06
CVS's Dividend Yield % is ranked higher than
84% of the 31 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. CVS: 3.06 )
Ranked among companies with meaningful Dividend Yield % only.
CVS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.55  Med: 1.26 Max: 3.29
Current: 3.06
0.55
3.29
Dividend Payout Ratio 0.66
CVS's Dividend Payout Ratio is ranked lower than
53% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.27 vs. CVS: 0.66 )
Ranked among companies with meaningful Dividend Payout Ratio only.
CVS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.23 Max: 0.66
Current: 0.66
0.11
0.66
3-Year Dividend Growth Rate 22.10
CVS's 3-Year Dividend Growth Rate is ranked higher than
62% of the 8 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.40 vs. CVS: 22.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
CVS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -33.8  Med: 8 Max: 37
Current: 22.1
-33.8
37
Forward Dividend Yield % 2.86
CVS's Forward Dividend Yield % is ranked higher than
82% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.33 vs. CVS: 2.86 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 8.69
CVS's 5-Year Yield-on-Cost % is ranked higher than
84% of the 38 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.89 vs. CVS: 8.69 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CVS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.67  Med: 3.83 Max: 10
Current: 8.69
1.67
10
3-Year Average Share Buyback Ratio 3.80
CVS's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: -0.50 vs. CVS: 3.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.9  Med: -0.4 Max: 4.7
Current: 3.8
-22.9
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.63
CVS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.08 vs. CVS: 0.63 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CVS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.35 Max: 20.37
Current: 0.63
0.55
20.37
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.30
CVS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
78% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. CVS: 1.30 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
CVS' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.54  Med: 0.81 Max: 1.57
Current: 1.3
0.54
1.57
Price-to-Median-PS-Value 0.68
CVS's Price-to-Median-PS-Value is ranked higher than
83% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.19 vs. CVS: 0.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.05 Max: 2.91
Current: 0.68
0.48
2.91
Price-to-Peter-Lynch-Fair-Value 3.73
CVS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
64% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.09 vs. CVS: 3.73 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CVS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.68 Max: 36.41
Current: 3.73
0.48
36.41
Earnings Yield (Greenblatt) % 5.98
CVS's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.22 vs. CVS: 5.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.65  Med: 9.2 Max: 16
Current: 5.98
5.65
16
Forward Rate of Return (Yacktman) % 14.02
CVS's Forward Rate of Return (Yacktman) % is ranked higher than
62% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.01 vs. CVS: 14.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CVS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.8  Med: 16.8 Max: 21.6
Current: 14.02
11.8
21.6

More Statistics

Revenue (TTM) (Mil) $188,055.00
EPS (TTM) $ 3.02
Beta1.26
Volatility37.64%
52-Week Range $60.14 - 82.15
Shares Outstanding (Mil)1,293.20

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 193,769 252,569 258,750
EBIT (Mil $) 10,798 14,565 17,422
EBITDA (Mil $) 11,870 17,096 19,423
EPS ($) 3.95 6.50 7.79
EPS without NRI ($) 3.95 6.50 7.79
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.98%
Dividends per Share ($) 1.95 2.02 2.13

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}